Mitesh

The reimbursement prices for the first 11 multi-source products moving from Category C to the new Category H have been published in the March 2026 Drug Tariff. Prices for 6 products have increased whereas 5 products have seen a decrease compared to their previous Category C prices. Ursodeoxycholic acid 500mg tablets (100) has the largest [...]

The post Prices for first 11 Category H products published in the March 2026 Drug Tariff appeared first on Community Pharmacy England.

A falsified version of Mounjaro (tirzepatide) KwikPen 15mg solution for injection has been found supplied through one online pharmacy in the UK. The falsified product is labelled with batch D873576 and applies to Mounjaro KwikPen 15mg solution for injection in pre-filled pen only. The issue was identified due to faults with the pens, where in [...]

The post MHRA Drug Safety Update: Falsified Mounjaro KwikPen 15mg pre-filled pens appeared first on Community Pharmacy England.

Following the completion of a safety review and the recommendations of the Commission on Human Medicines (CHM), the IXCHIQ Chikungunya vaccine is no longer indicated for adults over the age of 60 years, and is contraindicated in all individuals with hypertension, cardiovascular disease, diabetes mellitus, and/or chronic kidney disease. This action follows very rare fatal [...]

The post MHRA Drug Safety Update: IXCHIQ Chikungunya vaccine – updates to restrictions of use following safety review appeared first on Community Pharmacy England.

Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined the January 2026 concessionary price for Rosuvastatin 10mg tablets and Trimethoprim 100mg tablets: Drug Pack size Price concession Rosuvastatin 10mg tablets 28 £4.48 (previously £2.70) Trimethoprim 100mg tablets 28 £4.08 (previously £3.77) [...]

The post Improved price concession for Rosuvastatin 10mg tablets & Trimethoprim 100mg tablets for January 2026 appeared first on Community Pharmacy England.

Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden deterioration in vision, usually in one eye at a time, has been very rarely reported in association with semaglutide in the treatment of type 2 diabetes, weight management and cardiovascular risk reduction. Patients reporting a sudden loss of vision (including partial loss) while [...]

The post MHRA Drug Safety Update: Semaglutide (Wegovy®, Ozempic® and Rybelsus®): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) appeared first on Community Pharmacy England.